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i.org/1information on association with clinical variables and prognosis is limited. Potassium
measurements at admission were available in 1,867 patients with AHF in the original cohort
of 2,033 patients included in the Patients Hospitalized with acute heart failure and Volume
Overload to Assess Treatment Effect on Congestion and Renal FuncTion trial. Patients
were grouped according to low potassium (<3.5 mEq/l), normal potassium (3.5 to 5.0 mEq/l),
and high potassium (>5.0 mEq/l) levels. Results were veriﬁed in a validation cohort of 1,023
patients. Mean age of patients was 71 – 11 years, and 66% were men. Low potassium was
present in 115 patients (6%), normal potassium in 1,576 (84%), and high potassium in 176
(9%). Potassium levels increased during hospitalization (0.18 – 0.69 mEq/l). Patients with
high potassium more often used angiotensin-converting enzyme inhibitors and mineralo-
corticoid receptor antagonists before admission, had impaired baseline renal function and a
better diuretic response (p [ 0.005), independent of mineralocorticoid receptor antagonist
usage. During 180-day follow-up, a total of 330 patients (18%) died. Potassium levels at
admission showed a univariate linear association with mortality (hazard ratio [log] 2.36,
95% conﬁdence interval 1.07 to 5.23; p [ 0.034) but not after multivariate adjustment.
Changes of potassium levels during hospitalization or potassium levels at discharge were
not associated with outcome after multivariate analysis. Results in the validation cohort
were similar to the index cohort. In conclusion, high potassium levels at admission are
associated with an impaired renal function but a better diuretic response. Changes in po-
tassium levels are common, and overall levels increase during hospitalization. In conclu-
sion, potassium levels at admission or its change during hospitalization are not associated
with mortality after multivariate adjustment.  2016 The Authors. Published by Elsevier
Inc. This is an open access article under the CC BY license (http://creativecommons.org/
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0.1016/j.amjcard.2016.09.038Serum potassium is routinely measured during hospital-
ization for acute heart failure (AHF), and heart failure (HF)
guidelines recommend daily assessment of potassium during
treatment with intravenous loop diuretics.1 Potassium levels
at admission are associated with loop diuretic therapy and
intensive neurohormonal activation.2e5 In chronic HF, low
serum potassium levels were found to be associated with
increased mortality.4,6 However, a recent study in an AHF
population with a reduced ejection fraction (HFrEF; left
ventricular ejection fraction [LVEF] <35%) showed no
association between potassium levels at admission or a
change in potassium during hospitalization and clinical
outcome.7 Nonetheless, this study only focused on a HFrEF
population, and no information was available on diuretics
and diuretic response, which can confound ﬁndings.8 Data
on the clinical importance of potassium in patients with
AHF with both reduced and preserved ejection fraction are
absent.7,9 Current guidelines recommend to keep potassium
levels from 4.5 to 5.5 mmol/l; however, recommendations
for AHF are lacking.1,3 Therefore, in the present study, weccess article www.ajconline.org
Heart Failure/Serum Potassium Levels and Outcome in AHF 291investigated the association between serum potassium levels
at admission, changes during hospitalization, and the asso-
ciation with clinical characteristics and mortality.
Methods
The study population was a subcohort of the Patients
Hospitalized with acute heart failure and Volume Overload
to Assess Treatment Effect on Congestion and Renal
FuncTion (PROTECT) trial of which results and study
design have been published previously.10,11 In brief, the
PROTECT trial investigated the role of the selective A1
adenosine receptor antagonist rolofylline on treatment ef-
fect, deﬁned as a trichotomous end point of failure, un-
changed, and success. The study originally included 2,033
patients with a history of HF admitted with AHF. Potassium
measurements were available in 1,867 patients at admission.
In the PROTECT trial, patients with serum potassium levels
below <3.0 mEq/l were excluded, and patients with serum
potassium levels from 3.0 to 3.5 mEq/l were allowed if
parental supplemental potassium was administered.
Results of survival analysis were veriﬁed in a validation
cohort in the Coordinating Study Evaluating Outcomes of
Advising and Counseling Failure (COACH) of which
design and results have been published before.12,13 In brief,
the COACH trial studied the effects of additional basic and
intensive nurse-led support on the combined end point of
death and HF hospitalization of 1,023 patients with HF who
were admitted for AHF. The results of this trial were neutral.
Potassium levels were available in 999 patients at admission
and 1,023 patients at discharge. Patients in this trial were
included independent of potassium levels. Estimated
glomerular ﬁltration rate (eGFR) was based on the simpli-
ﬁed Modiﬁcation of Diet in Renal Disease formula, and HF
with a preserved ejection fraction was deﬁned as having a
LVEF >45%.14
For baseline characteristics, potassium levels were
divided into 3 groups based on cut-off values of <3.5, 3.5 to
5.0, and >5.0 mEq/l (low, normal, and high).4 Hypokalemia
was deﬁned as a potassium level <3.5 mEq/l and hyper-
kalemia as a potassium level >5.5 mEq/l. In the PROTECT
trial, discharge potassium was deﬁned as potassium levels at
day 7 after admission or at discharge, whichever came ﬁrst.
In the COACH trial, potassium was measured around
discharge. The change in potassium levels during hospital-
ization was determined as the difference between potassium
levels at admission and discharge. The primary end point for
this substudy of the PROTECT trial was all-cause mortality
at 180 days. The primary end point used for this substudy of
the COACH trial was all-cause mortality at 3 years.
Continuous variables are presented as means  standard
deviations or medians with interquartile ranges. Categorical
variables are presented as numbers with percentages. Inter-
group differences were analyzed using the KruskaleWallis
1-way analysis of variance, the 1-way analysis of variance,
or the chi-square test where appropriate.
For further analysis, potassium variables were log-
transformed to achieve normal distribution as this pro-
vided the best ﬁt in this population despite expectations of a
U-shaped relation. Survival differences between low,
normal, and high potassium are graphically depicted usingKaplaneMeier curves. Differences are tested using the log-
rank test. Survival analysis is performed using Cox regres-
sion analysis. Model ﬁt was tested using multifractional
polynomials. In addition, goodness of ﬁt was tested using
the Grønnesby and Borgan variation of the Hos-
mereLemeshow test.
Multivariate correction was done in the index cohort with
an established risk engine for this population which includes
8 variables measured at admission, namely age, previous HF
hospitalizations, peripheral edema, systolic blood pressure,
serum sodium, urea, creatinine, and albumin levels.15 In the
validation cohort, the COACH risk engine was used for
multivariate correction. The COACH risk engine includes
gender; age; pulse pressure; diastolic blood pressure; a
history of stroke, diabetes, peripheral vascular disease, and
myocardial infarction; estimated glomerular ﬁltration rate;
previous HF hospitalizations; sodium; LVEF; and levels of
N-terminal pro-b-type natriuretic peptide.16
All tests were performed 2 sided, and a p value of <0.05
was considered signiﬁcant. All statistical analyses were
performed using STATA version 11.0 (StataCorp LP, Col-
lege station, Texas).
Results
Table 1 provides the baseline characteristics of the main
study population. Baseline characteristics of the validation
cohort are presented in Supplementary Table 1. Of patients
enrolled in the PROTECT trial, 115 patients (6%) had low,
1,576 (84%) had normal, and 176 (9%) had high potassium
levels. Hyperkalemia (>5.5 mEq/l) at baseline was present
in 54 patients (1%). Overall, potassium levels increased
during hospitalization (0.18  0.69), yet 566 patients (34%)
experience a decrease in potassium levels. In a total of 909
patients (55%), the potassium level increased during hos-
pitalization, and only 100 patients (6%) had no change in
potassium levels (deﬁned as no change at all). Higher po-
tassium levels at admission were associated with higher
rates of diabetes, more previous usage of angiotensin-
converting enzyme (ACE) inhibition and mineralocorticoid
receptor antagonists (MRA), and a lower eGFR. Plasma
BNP levels were similar Treatment with MRAs was most
often changed during hospitalization (Figure 1). The asso-
ciation between baseline serum potassium levels, random-
ized treatment, and clinical outcomes is presented in
Table 2. Diuretic response expressed as kilograms of weight
loss per 40 mg of furosemide was lower for patients with
low potassium from admission to day 4 after admission
(p ¼ 0.005, Table 2). When examining tertiles of diuretic
response, patients with higher potassium were more often in
the higher tertile (p value for trend ¼ 0.002, Figure 2). Also,
when correcting for previous MRA usage (b 0.089,
p <0.001) or a change in MRA usage during hospitalization
(b 0.085, p ¼ 0.001), potassium levels at admission
remained associated with diuretic response. Serum potas-
sium levels were not associated with the trichotomous pri-
mary end point of the PROTECT study (p ¼ 0.800,
Table 2).
Patients with high and low levels of potassium had
higher mortality rates within the ﬁrst 7 days compared to
patients with normal potassium levels. Multifractional
Table 1
Baseline characteristics (PROTECT)
Variable Serum Potassium (mEq/L) p- value
3.0-3.4 (n¼115) 3.5-5.0 (n¼1576) >5.0 (n¼176)
Potassium levels at admission (mEq/L) 3.3 (3.2, 3.4) 4.2 (3.9, 4.5) 5.3 (5.2, 5.7) NA
Treatment allocation (% rolofylline) 76 (66%) 1051 (67%) 119 (68%) 0.959
Age (Years) 69  11 70  12 69  10 0.310
Men 74 (64%) 1055 (66%) 117 (67%) 0.850
Left ventricular ejection fraction 30 (20, 45) 30 (22, 40) 29 (20, 40) 0.910
Heart failure with a preserved ejection fraction 10 (18%) 113 (15%) 11 (13%) 0.740
NYHA class 0.660
I/II 23 (21%) 267 (18%) 26 (15%)
III 54 (50%) 763 (51%) 84 (49%)
IV 32 (29%) 463 (31%) 60 (35%)
Body mass index (kg/m2) 29  7 29  6 29  6 0.930
Systolic blood pressure (mmHg) 125  19 124  18 124  17 0.880
Diastolic blood pressure (mmHg) 74  12 74  12 74  12 0.990
Coronary Heart Disease 86 (75%) 1083 (69%) 126 (72%) 0.330
Hypertension 82 (71%) 1260 (80%) 138 (78%) 0.084
Diabetes mellitus 51 (44%) 697 (44%) 97 (55%) 0.023
Atrial Fibrillation 66 (57%) 859 (55%) 83 (47%) 0.130
Chronic obstructive pulmonary disease 31 (27%) 301 (19%) 37 (21%) 0.120
Potassium day 7 (mEq/L) 4.1 (3.8, 4.4) 4.5 (4.1, 4.9) 4.9 (4.4, 5.2) <0.001
Creatinine (mg/dL) 1.3 (1.1, 1.6) 1.4 (1.1, 1.7) 1.7 (1.3, 2.2) <0.001
eGFR (mL/min/1.73m2) 48  17 46  20 37  17 <0.001
BUN (mg/dL) 26 (20, 36) 29 (22, 40) 38 (28, 50) <0.001
Sodium (mEq/L) 141 (138, 143) 140 (137, 142) 143 (142, 141) <0.001
BNP (pg/mL) 495 (267, 885) 456 (258, 805) 426 (233, 826) 0.678
Orthopnea 94 (83%) 1311 (84%) 147 (85%) 0.950
Rales 13 (11%) 150 (10%) 19 (11%) 0.740
Edema 39 (34%) 414 (26%) 53 (30%) 0.130
Increased jugular venous pressure 42 (40%) 568 (40%) 69 (46%) 0.350
Prior medication use
ACE-inhibitors 57 (50%) 967 (64%) 128 (73%) <0.001
Angiotensin receptor blocker 21 (18%) 254 (16%) 16 (9%) 0.037
Beta-blockers 86 (75%) 1212 (77%) 133 (76%) 0.810
Calcium-channel blockers 15 (13%) 210 (13%) 28 (16%) 0.630
Digoxin 35 (30%) 444 (28%) 48 (27%) 0.840
Mineralocorticoid receptor antagonist 43 (37%) 672 (43%) 104 (59%) <0.001
p-values below the signiﬁcance threshold of 0.05 are indicated in bold.
Figure 1. Stacked bar graphs showing changes in medication dosage for ACE inhibitors/angiotensin II receptor blockers (ARB), b blockers, and aldosterone
receptor blockers stratiﬁed according to low (3.0 to 3.4), normal (3.5 to 5.0), and high potassium (>5.0) in PROTECT. p Value for difference is 0.942 for b
blockers, 0.183 for ACEi/ARB, and <0.001 for aldosterone receptor blockers.
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tassium levels and outcome was linear. Serum potassium
levels at admission showed a univariably signiﬁcant asso-
ciation with 180-day all-cause mortality in PROTECT
(Figure 3, Table 3). When corrected for age and gender,
predictive power was maintained. When adding eGFR to the
model, predictive power was lost. When correcting for thevariables included in the PROTECT risk engine, serum
potassium was not a signiﬁcant predictor of mortality.
A change in serum potassium levels (deﬁned as the dif-
ference between admission and discharge or day 7, which-
ever came ﬁrst) was associated with mortality, but not after
multivariate analysis. Potassium levels at discharge or day
7 were not associated with all-cause mortality (Table 3).
Table 2
Treatment and clinical outcomes (PROTECT)
Variable Serum Potassium (mEq/L) p-value
3.0-3.4(n¼115) 3.5-5.0 (n¼1576) >5.0 (n¼176)
Change of weight from day 1-4 weight loss (kg) -2.1 (-4, -.9) -2.2 (-4.1, -1) -2.7 (-4.4, -1.4) 0.170
IV loop diuretics total dose (mg)
Day 1 100 (60, 175) 80 (40, 140) 80 (40, 120) 0.013
Day 7 110 (60, 165) 100 (60, 200) 120 (60, 160) 0.950
Average daily IV dose day1-day7 51 (23, 97) 37 (17, 79) 40.0 (20, 73) 0.035
Oral loop diuretics dose (mg)
Day 1 80 (40, 120) 40 (40, 80) 40 (40, 80) 0.006
Day 7 80 (40, 120) 60 (40, 80) 40 (40, 80) 0.001
Total diuretic dose (mg)
Day 1 120 (60, 180) 80 (60, 160) 80 (51, 140) 0.014
Day 7 40 (20, 80) 40 (20, 7) 35 (20, 61) 0.030
Weight loss per 40mg furosemide (kg) -.34 (-.71, -.10) -.38 (-.80, -.13) -.48 (-.98, -.21) 0.005
Trichotomous outcome 0.800
Failure 28 (24%) 346 (22%) 41 (23%)
Unchanged 43 (37%) 588 (37%) 71 (40%)
Success 44 (38%) 642 (41%) 64 (36%)
Persistent renal impairment 24 (21%) 220 (14%) 30 (17%) 0.083
Worsening of heart failure 11 (10%) 178 (11%) 20 (11%) 0.406
Death 3 (2.6%) 24 (1.5%) 8 (4.6%) 0.016
Increase in creatinine 19 (17%) 192 (12%) 21 (12%) 0.346
Failure hemoﬁltration 2 (1.7%) 8 (0.5%) 2 (1.1%) 0.308
Death; cardiovascular; renal rehospitalization at 60 days 33 (29%) 456 (29%) 50 (28.4%) 0.990
Death; heart failure rehospitalization at 60 days 27 (24%) 340 (22%) 41 (23.3%) 0.793
Death; rehospitalization at 60 days 37 (32%) 538 (34%) 55 (31.3%) 0.700
p-values below the signiﬁcance threshold of 0.05 are indicated in bold.
Figure 2. Stacked bar graphs showing tertiles of diuretic response according
to low (3.0 to 3.4), normal (3.5 to 5.0), and high potassium (>5.0) in
PROTECT. p Value for trend is 0.002.
Figure 3. KaplaneMeier curves stratiﬁed according to low (3.0 to 3.4),
normal (3.5 to 5.0), and high potassium (>5.0) in PROTECT.
Heart Failure/Serum Potassium Levels and Outcome in AHF 293When looking at differential predictive value in subgroups,
no signiﬁcant interactions were found for age, gender, eGFR,
a history of myocardial infarction, diabetes, hypertension,
atrial ﬁbrillation, or HF status (Supplementary Figure 1,
available online). In the COACH cohort, 67 patients (6.7%)
had hypokalemia (<3.5 mEq/l), and 33 patients (3.3%) had
hyperkalemia (>5.5 mEq/l) at baseline. Serum potassium
was associated with 3-year all-cause mortality in univariate
analysis (Figure 4, Table 3) even when corrected for age and
gender. After adjusting for eGFR, potassium was no longerassociated with clinical outcome, as well as when adjustment
was performed for the variables included in the COACH risk
engine. Change of potassium levels between admission and
discharge was not associated with outcome. Potassium levels
at discharge were signiﬁcantly associated with outcome in
univariate analysis. However, signiﬁcance was lost in
multivariate analysis (Table 3).
Discussion
In the present study, we evaluated serum potassium
levels and their association with outcome in a heterogeneous
Table 3
Cox regression
PROTECT
(HR; 95%CI; p-value)
COACH
(HR; 95%CI; p-value)
Admission
Univariable 2.36 (1.07-5.23) 0.034 3.57 (1.84-6.93) <0.001
Model 1 2.54 (1.13-5.70) 0.023 2.99 (1.52-5.86) 0.002
Model 2 1.63 (0.72-3.67) 0.237 1.58 (0.80-3.10) 0.186
Model 3 1.36 (0.61-3.07) 0.453 1.35 (0.49-3.72) 0.563
Change*
Univariable 0.82 (0.68-0.98) 0.028 0.89 (0.78-1.03) 0.118
Model 1 0.83 (0.69-0.99) 0.041 0.92 (0.80-1.06) 0.263
Model 2 0.87 (0.73-1.05) 0.156 0.90 (0.79-1.04) 0.148
Model 3 0.98 (0.82-1.17) 0.815 0.89 (0.71-1.12) 0.313
Discharge†
Univariable 0.74 (0.30-1.81) 0.503 2.50 (1.10-5.66) 0.028
Model 1 0.84 (0.34-2.12) 0.724 2.40 (1.07-5.41) 0.034
Model 2 0.79 (0.32-1.98) 0.617 1.29 (0.57-2.94) 0.537
Model 3 1.02 (0.41-2.54) 0.960 0.63 (0.18-2.25) 0.480
Model 1: corrected for age and sex, Model 2: corrected for age, sex and
eGFR, Model 3: corrected for the PROTECT 8-variable risk model in
PROTECT and the COACH risk model in COACH.
p-values below the signiﬁcance threshold of 0.05 are indicated in bold.
* Between admission and day of discharge in COACH, between
admission and day 7 or day of discharge if day of discharge is before day 7
in PROTECT.
† Day of discharge in COACH, day 7 or day or day of discharge if day of
discharge is before day 7 in PROTECT.
Figure 4. KaplaneMeier curves stratiﬁed according to low (<3.5), normal
(3.5 to 5.0), and high potassium (>5.0) in COACH.
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both cohorts, patients with higher serum potassium levels
had worse outcomes; however, this association was not in-
dependent of established risk factors, in particular renal
function. These results were conﬁrmed in an unbiased and
independent cohort.
Our study shows that overall potassium levels increase
during hospitalization and that changes in potassium levels
are common during hospitalization for AHF. However, with
intensive diuretic treatment, one would expect overall po-
tassium levels to reduce during hospitalization as potassium
is excreted together with sodium by the transporter on which
loop diuretics act.8,17 In the Efﬁcacy of VasopressinAntagonism in HF Outcome Study with Tolvaptan
(EVEREST) study, a mild increase of potassium levels be-
tween admission and discharge was found in the overall
population.7 This can potentially be explained by the treat-
ment choices that were based on potassium levels, in which
patients with lower potassium would be less intensively
treated with diuretics and given potassium supplementation.
Interestingly, eGFR was lower in patients with a decrease in
potassium levels between admission and discharge in the
same cohort. Indeed, also in our study, eGFR was lower in
patients with higher potassium levels. This can potentially
be explained by that high potassium levels in this cohort
reﬂect a worse renal function, a ﬁnding which has been
described previously.18,19
Conversely, patients with higher serum potassium were
found to have a better diuretic response in this cohort. One
reason could be that diuretic response is not dependent on
kidney function alone as suggested by earlier evidence.20,21
Previous studies reported on the relation between potassium
and diuretic response.22,23 In the ﬁrst study, an improved
diuretic response was found in patients with higher levels of
potassium at admission. In the second study, low potassium
was one of the strongest predictors of a poor diuretic
response in multivariate analysis. In addition, potassium
supplementation was suggested to improve survival when
given together with diuretic therapy.24 Based on these
ﬁndings, potassium might be a target for therapy to improve
diuretic response through targeting patients with low po-
tassium levels with supplementation. However, manage-
ment choices confound these ﬁndings. Indeed, also in this
cohort, patients with low levels of potassium were less often
treated with ACE inhibition. This suggest that patients who
are unable to be uptitrated to guideline-directed medication
dosages due to either too high or too low potassium levels
might have a worse diuretic response. However, no data are
available on the interaction between guideline-directed
treatment and diuretic response, and this would require
further study.
So far, contradicting data concerning the predictive value
of potassium in different HF populations have been pub-
lished.4 In chronic HF, a substudy from the Randomized
Aldactone Evaluation Study trial found that an increase in
potassium levels after spironolactone treatment was not
associated with an increase in mortality.25,26 Also, in the
Eplerenone in Mild Patients Hospitalization and Survival
Study in Heart Failure, hyperkalemia did not interfere with
the survival beneﬁt of the study drug.27 In patients with
acute HF with reduced ejection fraction, no independent
predictive value of potassium was found, which is
conﬁrmed by this study for both patients with a reduced and
preserved ejection fraction.7 Of note, a positive univariate
association was found in this study between potassium
levels at admission and all-cause mortality. However, pre-
dictive value was attenuated when corrected for renal
function in multivariate analysis. This suggests that potas-
sium levels at admission and during hospitalization for AHF
reﬂect clinical associations and do not have an independent
effect on mortality.9,28 Following, potassium levels at
admission and changes during hospitalization can be
considered to be a surrogate marker, reﬂecting clinical
characteristics such as renal function and diabetes.7
Heart Failure/Serum Potassium Levels and Outcome in AHF 295This is a post hoc analysis of 2 randomized controlled
trials, which could have induced selection bias. Further-
more, the PROTECT trial excluded patients with potassium
levels <3.5 mEq/l, where patients with levels of potassium
from 3.0 to 3.4 mEq/l were allowed if parental supplemental
potassium was administered. However, no such limitations
were present in COACH. Unfortunately, no information was
available on potassium supplementation in both the PRO-
TECT and COACH cohorts. However in a different study,
no effect of potassium supplementation on all-cause mor-
tality was found, suggesting that its effects as a confounder
are limited.29 In addition, no information was available on
usage of thiazide diuretics. Furthermore, potassium levels at
admission for AHF might inform treatment management
decisions, inﬂuencing outcomes.
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